Dexamethason

( DrugBank: - / KEGG DRUG: - )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3
28	全身性アミロイドーシス	87

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	3
331	特発性多中心性キャッスルマン病	1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: ...	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federati ...
2	NCT00674141 (ClinicalTrials.gov)	July 2008	6/5/2008	Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment	Nasal Administration of Dexamethasone for MS Treatment	MS Patient With Relpasing Remitting Attacks	Drug: Dexamethasone soduim phosphate	Hadassah Medical Organization	NULL	Withdrawn	18 Years	N/A	Both	10	Phase 1	Israel
3	EUCTR2006-003113-40-NL (EUCTR)	18/08/2006	21/07/2006	Dexamethason for the treatment of exacerbations in multiple sclerosis	Dexamethason for the treatment of exacerbations in multiple sclerosis	Multiple Sclerosis MedDRA version: 8.1;Level: PT;Classification code 10028245;Term: Multiple scleros ...	Product Name: Dexamethason INN or Proposed INN: Dexamethasone	Department of Neurology UMCG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60		Netherlands

First Previous1Next Last

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

trials per page:

Showing 1 to 10 of 87 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05486481 (ClinicalTrials.gov)	April 1, 2023	1/8/2022	Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation ( ...	A Multicenter Phase 1/2 Study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Sys ...	AL Amyloidosis;Light Chain (AL) Amyloidosis;Systemic Light Chain Disease	Drug: Venetoclax;Drug: Dexamethasone;Drug: Daratumumab	Sandy Wong, MD	Janssen Pharmaceuticals;AbbVie	Not yet recruiting	18 Years	N/A	All	78	Phase 1/Phase 2	United States
2	NCT05451771 (ClinicalTrials.gov)	October 26, 2022	6/7/2022	Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Sy ...	AL Amyloidosis	Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: D ...	Rajshekhar Chakraborty, MD	Genentech, Inc.	Recruiting	18 Years	N/A	All	53	Phase 1/Phase 2	United States
3	JPRN-jRCT2031220037	20/06/2022	23/04/2022	A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloido ...	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of B ...	Light Chain (AL) Amyloidosis	- Birtamimab group: Intravenous administration of 24 mg/kg birtamimab every 28 days. Bortezomib-conta ...	Nie Christie	NULL	Recruiting	>= 18age old	Not applicable	Both	16	Phase 3	Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Republic ...
4	NCT05066607 (ClinicalTrials.gov)	February 11, 2022	24/8/2021	Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in V ...	A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus P ...	AL Amyloidosis	Drug: Isatuximab	Intergroupe Francophone du Myelome	Sanofi;Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	46	Phase 2	France
5	NCT04984330 (ClinicalTrials.gov)	December 2021	29/7/2021	Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease	Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease	Amyloid;Amyloidosis;AL Amyloidosis	Drug: Selinexor;Drug: Dexamethasone	Weill Medical College of Cornell University	Karyopharm Therapeutics Inc	Withdrawn	18 Years	N/A	All	0	Early Phase 1	United States
6	NCT04754945 (ClinicalTrials.gov)	April 28, 2021	9/2/2021	Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis	Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy	AL Amyloidosis	Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Isatuximab	Emory University	Sanofi;National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	25	Phase 1	United States
7	NCT04270175 (ClinicalTrials.gov)	April 14, 2021	12/2/2020	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Amyloid;AL Amyloidosis;Refractory AL Amyloidosis	Drug: Daratumumab;Drug: Pomalidomide;Drug: Dexamethasone	Weill Medical College of Cornell University	Janssen Scientific Affairs, LLC	Recruiting	18 Years	N/A	All	21	Phase 2	United States
8	NCT04504825 (ClinicalTrials.gov)	February 2, 2021	20/7/2020	A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloido ...	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasm ...	AL Amyloidosis	Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen ...	Alexion	NULL	Recruiting	18 Years	N/A	All	124	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Jap ...
9	NCT04512235 (ClinicalTrials.gov)	November 12, 2020	10/8/2020	A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloido ...	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasm ...	AL Amyloidosis	Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen ...	Alexion	NULL	Recruiting	18 Years	N/A	All	267	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Jap ...
10	NCT04115956 (ClinicalTrials.gov)	August 6, 2020	29/8/2019	A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglob ...	An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Follo ...	AL Amyloidosis	Drug: Melphalan-Flufenamide (Melflufen);Drug: Dexamethasone	Oncopeptides AB	PRA Health Sciences	Terminated	18 Years	N/A	All	6	Phase 1/Phase 2	United States;Czechia;France;Germany;Greece;Israel;Norway;Spain;United Kingdom;Italy;Poland

First Previous1 2 3 4 5…9Next Last

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02666443 (ClinicalTrials.gov)	September 2016	24/1/2016	Low Dose Dexamethasone in Supraclavicular Blocks	Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Rando ...	Rheumatoid Arthritis;Osteoarthritis;Nerve Entrapment;Ligament Injury	Drug: Control intervention (no dexamethasone);Drug: Peri-neural Dexamethasone 1 mg;Drug: Intravenous ...	University of Calgary	NULL	Recruiting	18 Years	80 Years	Both	306	N/A	Canada
2	EUCTR2009-017051-10-NL (EUCTR)	13/07/2010	25/05/2010	Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis	Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis	Patients with rheumatoid arthritis, who suffer from a exacerbation of disease can be included in thi ...	Trade Name: Dexamethason Product Name: dexamethason	UMC Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
3	NCT00244153 (ClinicalTrials.gov)	June 2004	25/10/2005	Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis	Intraarticular Application of Opioids Versus Glucocorticosteroids Versus Placebo in Rheumatoid Arthr ...	Rheumatic Disease	Drug: intraarticular morphine;Drug: intraarticular dexamethasone	Charite University, Berlin, Germany	NULL	Recruiting	19 Years	N/A	Both	120	Phase 1/Phase 2	Germany

First Previous1Next Last

331. 特発性多中心性キャッスルマン病

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03982771 (ClinicalTrials.gov)	January 1, 2019	3/5/2019	BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)	Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Cast ...	Idiopathic Multicentric Castleman's Disease	Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethason	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China

First Previous1Next Last